Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time). Keytruda is used in adults and some children with certain advanced forms of the following types of ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

In oncology drugs, Keytruda sales are likely to have been ... is likely to have hurt sales of neuromuscular blockade medicine — Bridion injection. The Zacks Consensus Estimate for Bridion ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

Padcev may be given alone or in combination with pembrolizumab (Keytruda). In Padcev clinical ... For some people, Padcev injection can cause an allergic reaction. But it’s not clear whether ...

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

the antibody in its blockbuster cancer immunotherapy Keytruda. They found that the new version was more stable and suitable for subcutaneous injection. Earlier this year, meanwhile, another team ...